Latest news with #TarponSprings
Yahoo
30-06-2025
- Climate
- Yahoo
Prayers Pouring In For State Of Florida On Monday
Prayers Pouring In For State Of Florida On Monday originally appeared on The Spun. Prayers are pouring in for the state of Florida on this Monday morning. A major storm appears to be heading for the western coast of Florida on Monday morning. Iconic weatherman Jim Cantore issued a major warning for those on the western coast of Florida. A "surging bow" is heading for the western coast of Florida prior to 9 a.m. E.T. on Monday morning. It looks intense. "Surging bow heading into Tarpon Springs, FL/New Port Richey area with gusty winds, waterspouts offshore," he wrote. "Incoming!" "Wow that's crazy," one fan wrote after seeing a photo of the radar. "Let's go!!" another storm chaser said. As a reminder, here's what to do when significant weather hits: Stay Weather Ready: Continue to listen to local news or a NOAA Weather Radio to stay updated about severe thunderstorm watches and warnings. At Your House: Go to your secure location if you hear a severe thunderstorm warning. Damaging wind or large hail may be approaching. Take your pets with you if time allows. At Your Workplace or School: Stay away from windows if you are in a severe thunderstorm warning and damaging wind or large hail is approaching. Do not go to large open rooms such as cafeterias, gymnasiums or auditoriums. Outside: Go inside a sturdy building immediately if severe thunderstorms are approaching. Sheds and storage facilities are not safe. Taking shelter under a tree can be deadly. The tree may fall on you. Standing under a tree also put you at a greater risk of getting struck by lightning. In a Vehicle: Being in a vehicle during severe thunderstorms is safer than being outside; however, drive to closest secure shelter if there is sufficient time. Our thoughts are with everyone in the western part of Florida on this Monday morning. Stay safe and dry, everyone. Prayers Pouring In For State Of Florida On Monday first appeared on The Spun on Jun 30, 2025 This story was originally reported by The Spun on Jun 30, 2025, where it first appeared.
Associated Press
30-06-2025
- Business
- Associated Press
Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic
TARPON SPRINGS, Fla., June 30, 2025 -- Allarity Therapeutics, Inc. ('Allarity' or the 'Company') (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that IP Australia, the Australian Government agency that administers intellectual property rights in the country, has formally accepted the Company's patent application for its DRP® companion diagnostic specific to stenoparib. The acceptance covers 40 claims and marks a key step in Allarity's global strategy to protect the potential international commercialization of its proprietary DRP® platform alongside the clinical development of stenoparib. The granted patent will be officially advertised in the Australian Official Journal of Patents on June 26, 2025, followed by a three-month opposition period. If unopposed, the patent is expected to be granted within 20 working days thereafter. Thomas Jensen, CEO of Allarity Therapeutics, commented: 'This latest patent acceptance from Australia represents another important achievement in our efforts to secure international IP protection for our DRP® technology. As we continue advancing stenoparib through Phase 2 trials toward U.S. regulatory approval, we are also building a robust intellectual property position in key global markets.' Allarity previously secured a European patent for the Stenoparib DRP® and holds 18 granted patents for drug-specific DRPs, including eight in the United States. Patent applications for the Stenoparib DRP® remain pending in the U.S., Canada, Japan, China, and India. About Stenoparib Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib's unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121. About the Drug Response Predictor – DRP® Companion Diagnostic Allarity uses its drug-specific DRP® to select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform, which may be useful in all cancer types and is patented for dozens of anti-cancer drugs, has been extensively published in the peer-reviewed literature. About Allarity Therapeutics Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit Follow Allarity on Social Media LinkedIn: Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company's current expectations or forecasts of future events. The words 'anticipates,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predicts,' 'project,' 'should,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the expected grant and scope of the Australian patent for the Stenoparib DRP®; the anticipated contribution of this patent to the Company's global intellectual property strategy; and the Company's ability to advance and commercialize stenoparib in Australia and other key markets. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the potential for opposition to the patent grant; changes in regulatory timelines or requirements; failure to obtain regulatory approval for stenoparib or its companion diagnostic; and risks inherent in developing and commercializing biopharmaceutical products. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in our Form 10-K annual report filed with the Securities and Exchange Commission (the 'SEC') on March 31, 2025, available at the SEC's website at and as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law. ### Company Contact: [email protected] Media Contact: Thomas Pedersen Carrotize PR & Communications +45 6062 9390 [email protected] Attachment
Yahoo
07-06-2025
- Yahoo
Odyssey Cruises in Tarpon Springs offers family friendly educational experiences
The Brief Odyssey Cruises is run by small business owner Adam Smith. The main tour is a two-hour dolphin and shelling cruise. TARPON SPRINGS, Fla. - From dolphin sightings to seashell-covered shores, Odyssey Cruises gives guests a chance to experience the Gulf Coast like never before. It's a hands-on, educational experience built around wildlife, history and hidden treasure. Tarpon Springs' largest tour boat, owned and operated by Adam Smith, takes passengers from the historic Sponge Docks out to Anclote Key, a Florida state park only accessible by boat. "We try to keep it very educational, with a focus on family fun," Smith says. Its like "two tours in one," part of the time looking for dolphins, the rest shelling and swimming. Visitors can comb the shorelines for various shells and some lucky collectors may even stumble upon a Junonia, which Smith says is "a very rare shell that is found particularly on the gulf coast." "People that are experienced shellers will tell you that you don't find the shell - the shell finds you," Smith added. Local perspective For many in the Tampa Bay area, Odyssey Cruises has become a way to reconnect with Florida's natural coastline. The tours frequently draw shelling enthusiasts, hobbyists, and families alike. "Because it's pristine and undisturbed, it's a great place to go find shells. It's exciting having the folks come on board and show us their treasures." READ: City of Sarasota parking garages to go 'gateless' He's even seen guests turn their finds into hobbies or businesses. "A lot of folks get these seashells, take them home, clean them up, and make projects with them," he said. "They get very excited when they find the rare shells." Tours are available year-round, with departure times depending on the season, and can be booked on their website. The Source Information for this story was gathered by FOX 13's Jason Wright. STAY CONNECTED WITH FOX 13 TAMPA: Download the FOX Local app for your smart TV Download FOX Local mobile app: Apple | Android Download the FOX 13 News app for breaking news alerts, latest headlines Download the SkyTower Radar app Sign up for FOX 13's daily newsletter
Yahoo
18-05-2025
- Science
- Yahoo
Researching Goliath Grouper at the Tarpon Aquarium
The Brief A student seeking her Master's Degree is working on a new research project to show how smart the Goliath Grouper really is. Hannah Murray is creating her Master's Thesis project based on the interactions between the diver and the grouper. You can see Tarpon Aquarium's show with the 150-pound grouper each day. TARPON SPRINGS, Fla. - A Master's Degree seeking students' chance to visit the Tarpon Aquarium gave birth to a new research project to show how smart the Goliath Grouper really is. What they're saying "I'm a master's student at Unity Environmental University, which is based up in Maine," shared Hannah Murray. "I'm getting my Master's Degree in Marine Science. I came here as a guest for the first time, and I happened to see Paige's show with Oscar and was thoroughly impressed." Oscar is a Goliath Grouper at the Tarpon Springs Aquarium and Animal Sanctuary. Twice a day, the staff at the aquarium put on a show in the 75,000-gallon aquarium to show visitors the amazing creatures that live underneath the surface of the Gulf waters. One of those is the 150-pound grouper. "We are really excited to hopefully get to display the intelligence of the Goliath grouper that hasn't really been studied before," shared Paige Konger Henry. She's one of the owners at the aquarium and the diver who enters the tank daily. "His name is Oscar the Grouch. He has been with my family for about 13 years." Murray reached out to Konger Henry to inquire about creating her Master's Thesis project based on the interactions between the diver and the grouper. READ: FWC reminds people to be safe as boaters take to the water this summer "When she gets into the tank, he is honestly so excited to see her," recalled Murray. That made for a perfect setup for the study to incorporate some simple intelligence markers. Paige Konger Henry described it this way: "Throughout this research we've been trying to get him to do, essentially, tricks. After he picks up the new desired behavior, the new trick, if you will, we wait a few weeks and then ask for the trick again to see if he remembers it." Murray logs the training and notes the duration of time and the result when Konger Henry calls for the trick to happen again. The compiled results are a part of the overall thesis project. For Konger Henry, she is hoping for a different educational value to come out of the research. "When we see a fish, I don't think we value them beyond the dinner plate." What you can do You can see Oscar perform twice a day and at noon at the Tarpon Springs Aquarium. They are located at 1722 North Pinellas Avenue in Tarpon Springs. For their hours and other show information, visit their website. CLICK HERE:>>>Follow FOX 13 on YouTube The Source Information for this story was gathered by FOX 13's Jason Wright. STAY CONNECTED WITH FOX 13 TAMPA: Download the FOX Local app for your smart TV Download FOX Local mobile app: Apple | Android Download the FOX 13 News app for breaking news alerts, latest headlines Download the SkyTower Radar app Sign up for FOX 13's daily newsletter
